Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E35.47 EPS (ttm)1.84 Insider Own0.05% Shs Outstand2.75B Perf Week-1.56%
Market Cap178.91B Forward P/E15.57 EPS next Y4.18 Insider Trans-4.54% Shs Float2.73B Perf Month4.79%
Income5.09B PEG5.74 EPS next Q1.03 Inst Own75.60% Short Float0.70% Perf Quarter-1.56%
Sales40.02B P/S4.47 EPS this Y-10.00% Inst Trans-0.60% Short Ratio2.43 Perf Half Y3.09%
Book/sh14.43 P/B4.51 EPS next Y8.00% ROA5.30% Target Price70.11 Perf Year3.35%
Cash/sh4.36 P/C14.95 EPS next 5Y6.19% ROE12.50% 52W Range58.29 - 66.80 Perf YTD10.63%
Dividend1.88 P/FCF53.12 EPS past 5Y-7.00% ROI6.40% 52W High-2.50% Beta0.82
Dividend %2.89% Quick Ratio1.20 Sales past 5Y-3.70% Gross Margin76.40% 52W Low11.73% ATR0.66
Employees68000 Current Ratio1.50 Sales Q/Q0.90% Oper. Margin15.30% RSI (14)59.88 Volatility0.99% 0.96%
OptionableYes Debt/Eq0.63 EPS Q/Q63.70% Profit Margin12.70% Rel Volume0.93 Prev Close65.60
ShortableYes LT Debt/Eq0.55 EarningsOct 27 BMO Payout100.50% Avg Volume7.89M Price65.13
Recom2.30 SMA200.92% SMA502.66% SMA2002.85% Volume7,465,921 Change-0.72%
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Sep-23-17 12:44PM  This Google, Microsoft, Samsung-Targeting CCleaner Attack Sets an Insidious Trend Fortune
Sep-22-17 04:01PM  Apple, UnitedHealth Weigh on DJIA Friday 24/7 Wall St.
03:30PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) Business Wire
01:08PM  AstraZeneca Stock Upgraded: What You Need to Know Motley Fool
09:58AM  Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval Zacks
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
06:04AM  Better Buy: Celgene Corporation vs. Merck & Co., Inc. Motley Fool
Sep-20-17 08:46PM  Pfizer and Johnson & Johnson's Brewing Brawl Gets Real Motley Fool
03:50PM  2 Important Dates for Big Pharma GuruFocus.com
01:10PM  New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer CNW Group
Sep-19-17 07:00AM  Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer Business Wire
Sep-18-17 10:19AM  Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear InvestorPlace
09:42AM  The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 Motley Fool
Sep-15-17 08:02AM  Dow Jones Closes at New High GuruFocus.com
Sep-13-17 02:23PM  FDA panel unanimously votes to recommend GSK shingles vaccine Reuters
08:40AM  Major Pharma Short Interest Surges 24/7 Wall St.
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Sep-12-17 05:36PM  Bristol-Myers Reports Positive Results from Melanoma Study Zacks
02:20PM  Now Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients CNW Group
11:13AM  Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock InvestorPlace
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Sep-11-17 10:06AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
09:00AM  Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Business Wire
Sep-10-17 08:45AM  Mercks KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure Business Wire
Sep-09-17 08:45AM  Progression-Free Survival Data from ECHO-202 Trial of Incytes Epacadostat in Combination with Mercks KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma Business Wire
Sep-08-17 10:37AM  Inside Mercks Segment-Wise Performance in 2Q17 Market Realist
10:33AM  Mercks KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC Business Wire
09:40AM  Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval Zacks
09:07AM  Behind Mercks Revenues in 2Q17 Market Realist
08:20AM  Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold Zacks
08:00AM  Updated Data for Mercks KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress Business Wire
07:38AM  Understanding Mercks Valuation after 2Q17 Market Realist
07:20AM  Corporate News Blog - Merck to Acquire German immuno-oncology Company Rigontec ACCESSWIRE
06:18AM  Merck's immunotherapy, chemo mix shows extended lung cancer gains Reuters
Sep-07-17 06:05PM  Merck's immunotherapy, chemo mix shows extended lung cancer gains Reuters
01:07PM  FDA widens holds on immunotherapy combination blood cancer trials Reuters
10:32AM  Merck (MRK) Opts for Buying German Immuno-Oncology Biotech Zacks
08:58AM  Bristol-Myers kidney cancer drug meets early success, study stopped Reuters
08:00AM  Merck to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Business Wire
Sep-06-17 03:06PM  Merck just plowed millions into this start-up to help get drugs to market faster CNBC
12:28PM  Merck to buy privately-held biotech Rigontec for 115 mln euros upfront MarketWatch
12:20PM  Merck buys German immuno-oncology company in deal valued at up to $554M American City Business Journals
11:05AM  Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer Zacks
10:06AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
09:57AM  Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln Reuters
06:30AM  MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology Business Wire
06:30AM  Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology Business Wire
Sep-05-17 06:30AM  European Commission Approves Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer Business Wire
Sep-04-17 08:05AM  Key FDA Regulatory Events to Watch Out for in Sep 2017 Zacks
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Sep-02-17 08:05AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Sep-01-17 05:32PM  Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda Zacks
09:18AM  The Zacks Analyst Blog Highlights: Merck, Caterpillar, Intel, Analog Devices and Best Buy Zacks
Aug-31-17 05:10PM  Top Stock Reports for Merck, Caterpillar & Intel Zacks
03:02PM  Eli Lillys Valuations after Its 2Q17 Earnings Market Realist
08:05AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Aug-30-17 07:22PM  New and Updated Data for KEYTRUDA® (pembrolizumab) from Mercks Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress Business Wire
11:46AM  Merck: Heartbreak Over A Cholesterol Drug Barrons.com
09:13AM  Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9% Zacks
Aug-29-17 10:30AM  US Market Indexes Mostly Higher on Monday GuruFocus.com
08:45AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : August 29, 2017 Capital Cube
08:00AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
06:08AM  Merck cholesterol drug cuts heart risk only 9 pct, future unclear Reuters
05:00AM  Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors InvestorPlace
02:31AM  Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease Business Wire
02:30AM  Merck cholesterol drug cuts heart risk by 9 pct in study Reuters
Aug-28-17 05:52PM  ETFs with exposure to Merck & Co., Inc. : August 28, 2017 Capital Cube
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
07:36AM  Mercks Hospital Acute Care Business: A Post-2Q17 Update Market Realist
06:57AM  Novo Nordisk's Victoza Gets FDA Nod for Label Expansion Zacks
Aug-27-17 07:47AM  Here Are the Big Pharma Stocks to Own Based on R&D Spending Motley Fool
Aug-25-17 08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
12:09AM  [$$] Merck Is Good for Your Portfolios Health The Wall Street Journal
Aug-24-17 01:39PM  Options say these three stocks are ready to break out CNBC Videos
10:00AM  Doctors on the cusp of launching the first male contraceptive but still need to seduce Big Pharma CNBC
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
05:30AM  [$$] Merck Is Good for Your Portfolio's Health The Wall Street Journal
Aug-23-17 07:00AM  Tons of Companies Ditched Trump After Charlottesville. But Merck Got the Biggest Boost Fortune
Aug-22-17 10:31AM  Large-Cap Stocks Gain on Monday GuruFocus.com
09:07AM  How Allergans US Specialized Therapeutics Segment Performed in 2Q17 Market Realist
Aug-21-17 06:14PM  Zoetis (ZTS) Poised to Grow on Companion Animal Portfolio Zacks
11:48AM  Merck & Co., Inc. :MRK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017 Capital Cube
12:22AM  [$$] Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stock The Wall Street Journal
Aug-18-17 10:38AM  Opdivo Could Drive Bristol-Myers Squibbs Revenue Growth in 2017 Market Realist
10:10AM  Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada Zacks
10:01AM  AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion Zacks
08:00AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
07:09AM  Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo Zacks
07:00AM  [$$] Lost $12 Million Windfall Sparks Suit Against Delaware The Wall Street Journal
01:52AM  Corporate Americas, Wall Streets new mindset on Donald Trump American City Business Journals
Aug-17-17 05:23PM  FDA expands use of AstraZeneca/Merck ovarian cancer drug Reuters
04:35PM  FDA approves expanded use of AstraZeneca ovarian cancer drug Reuters
03:36PM  LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer Business Wire
12:17PM  Eli Lilly: Will A New Rival Hobble Its Top Growth Driver? Barrons.com
10:06AM  Can Pfizer Bank on New Immunotherapy Bavencio for Growth? Zacks
08:00AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
07:37AM  Sanofis Revenue Growth in 2Q17 Market Realist
Aug-16-17 07:18PM  Valeant's Papa: 'It's been a challenging 15 months, but w... CNBC Videos
05:38PM  Trump Council CEOs Had Been Pressured to Step Down For Months Fortune
05:08PM  CEO Timeline: Who Quit White House Councils When, And How Trump Reacted The Wall Street Journal
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborationS with Aduro Biotech, Inc.; Premier Inc.; Cancer Research Technology; Corning; Pfizer Inc.; and AstraZeneca PLC. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM